Risk factors for the progression of mild cognitive impairment to dementia

Clinics in Geriatric Medicine

Volumn 29, Issue 4, 2013, Pages 873-893

  Campbell, Noll L ^a,b,c,d   Unverzagt, Fred ^e   LaMantia, Michael A ^b,c,e   Khan, Babar A ^b,c,e   Boustani, Malaz A ^b,c,e  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^c REGENSTRIEF INSTITUTE   (United States)

^d Wishard Eskenazi Health Services   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Dementia; Genetics; Mild cognitive impairment; Risk factors

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; CLUSTERIN; DONEPEZIL; INSULIN; ORAL ANTIDIABETIC AGENT; TAU PROTEIN;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ANXIETY; BRAIN ATROPHY; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING; COMORBIDITY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; GENETIC RISK; GENOTYPE; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MEDICATION THERAPY MANAGEMENT; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SENILE PLAQUE; TEMPORAL LOBE; WHITE MATTER LESION;

BIOMARKERS; DEMENTIA; GENETICS; MILD COGNITIVE IMPAIRMENT; RISK FACTORS;

AGED; DEMENTIA; DISEASE PROGRESSION; HUMANS; MILD COGNITIVE IMPAIRMENT; RISK FACTORS;

EID: 84884798894     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2013.07.009     Document Type: Review

References (109)

1. Ganguli M., Petersen R.C. Mild cognitive impairment: challenging issues. Am J Geriatr Psychiatry 2008, 16(5):339-342.
2. Winblad B., Palmer K., Kivipelto M., et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. JIntern Med 2004, 256(3):240-246.
3. Petersen R.C. Mild cognitive impairment as a diagnostic entity. JIntern Med 2004, 256(3):183-194.
4. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56(3):303-308.
5. Petersen R.C., Smith G.E., Ivnik R.J., et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995, 273(16):1274-1278.
6. Smith G., Petersen R.C., Parisi J.E., et al. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cognit 1996, 3:131-147.
7. Graham J.E., Rockwood K., Beattie B.L., et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997, 349(9068):1793-1796.
8. Ebly E.M., Hogan D.B., Parhad I.M. Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol 1995, 52(6):612-619.
9. Kral V.A. Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962, 86:257-260.
10. Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994, 6(1):63-68.
11. Plassman B.L., Langa K.M., Fisher G.G., et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008, 148(6):427-434.
12. Boustani M.A., Sachs G.A., Alder C.A., et al. Implementing innovative models of dementia care: The Healthy Aging Brain Center. Aging Ment Health 2011, 15(1):13-22.
13. Yaffe K., Petersen R.C., Lindquist K., et al. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 2006, 22(4):312-319.
14. Mitchell A.J., Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. JNeurol Neurosurg Psychiatry 2008, 79(12):1386-1391.
15. Petersen R.C., Roberts R.O., Knopman D.S., et al. Mild cognitive impairment: ten years later. Arch Neurol 2009, 66(12):1447-1455.
16. Raffaitin C., Gin H., Empana J.P., et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009, 32(1):169-174.
17. Solfrizzi V., Scafato E., Capurso C., et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. JNeurol Neurosurg Psychiatry 2010, 81(4):433-440.
18. Vanhanen M., Koivisto K., Moilanen L., et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006, 67(5):843-847.
19. Razay G., Vreugdenhil A., Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007, 64(1):93-96.
20. Bowler J.V. Vascular cognitive impairment. JNeurol Neurosurg Psychiatry 2005, 76(Suppl 5):v35-v44.
21. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. NEngl J Med 2005, 352(23):2379-2388.
22. Doody R.S., Ferris S.H., Salloway S., et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009, 72(18):1555-1561.
23. Unverzagt F.W., Guey L.T., Jones R.N., et al. ACTIVE cognitive training and rates of incident dementia. JInt Neuropsychol Soc 2012, 18(4):669-677.
24. Aisen P.S., Thal L.J., Ferris S.H., et al. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res 2008, 5(1):73-82.
25. Snitz B.E., O'Meara E.S., Carlson M.C., et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009, 302(24):2663-2670.
26. DeKosky S.T., Williamson J.D., Fitzpatrick A.L., et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300(19):2253-2262.
27. Jack C.R., Shiung M.M., Weigand S.D., et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65(8):1227-1231.
28. Whitwell J.L., Shiung M.M., Przybelski S.A., et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008, 70(7):512-520.
29. McEvoy L.K., Fennema-Notestine C., Roddey J.C., et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009, 251(1):195-205.
30. Bakkour A., Morris J.C., Dickerson B.C. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009, 72(12):1048-1055.
31. Murphy E.A., Holland D., Donohue M., et al. Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls. Neuroimage 2010, 53(4):1310-1317.
32. Becker J.A., Hedden T., Carmasin J., et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011, 69(6):1032-1042.
33. Fjell A.M., Walhovd K.B., Fennema-Notestine C., et al. One-year brain atrophy evident in healthy aging. JNeurosci 2009, 29(48):15223-15231.
34. McDonald C.R., McEvoy L.K., Gharapetian L., et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 2009, 73(6):457-465.
35. Saykin A.J., Wishart H.A., Rabin L.A., et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006, 67(5):834-842.
36. de Leon M.J., Mosconi L., Blennow K., et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 2007, 1097:114-145.
37. Tondelli M., Wilcock G.K., Nichelli P., et al. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. Neurobiol Aging 2012, 33(4):825.e25-825.e36.
38. Geroldi C., Rossi R., Calvagna C., et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. JNeurol Neurosurg Psychiatry 2006, 77(11):1219-1222.
39. Breteler M.M., van Swieten J.C., Bots M.L., et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994, 44(7):1246-1252.
40. Scarpelli M., Salvolini U., Diamanti L., et al. MRI and pathological examination of post-mortem brains: the problem of white matter high signal areas. Neuroradiology 1994, 36(5):393-398.
41. Longstreth W.T., Manolio T.A., Arnold A., et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996, 27(8):1274-1282.
42. van der Flier W.M., van Straaten E.C., Barkhof F., et al. Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. JNeurol Neurosurg Psychiatry 2005, 76(11):1497-1500.
43. Yoshita M., Fletcher E., Harvey D., et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006, 67(12):2192-2198.
44. de Groot J.C., de Leeuw F.E., Oudkerk M., et al. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology 2001, 56(11):1539-1545.
45. Devine M.E., Fonseca J.A., Walker Z. Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia?. Int Psychogeriatr 2013, 25(1):120-127.
46. Debette S., Markus H.S. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010, 341:c3666.
47. Brickman A.M., Provenzano F.A., Muraskin J., et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol 2012, 69(12):1621-1627.
48. Bombois S., Debette S., Bruandet A., et al. Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. Stroke 2008, 39(7):2046-2051.
49. Hansson O., Zetterberg H., Buchhave P., et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5(3):228-234.
50. Mattsson N., Zetterberg H., Hansson O., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302(4):385-393.
51. Mattsson N., Portelius E., Rolstad S., et al. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. JAlzheimers Dis 2012, 30(4):767-778.
52. Fagan A.M., Mintun M.A., Mach R.H., et al. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59(3):512-519.
53. Heister D., Brewer J.B., Magda S., et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011, 77(17):1619-1628. Alzheimer's Disease Neuroimaging I.
54. Vos S., van Rossum I., Burns L., et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012, 33(10):2272-2281.
55. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):270-279.
56. van Rossum I.A., Visser P.J., Knol D.L., et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. JAlzheimers Dis 2012, 29(2):319-327.
57. Lee K.S., Chung J.H., Choi T.K., et al. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord 2009, 28(4):281-287.
58. Kamer A.R., Craig R.G., Pirraglia E., et al. TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. JNeuroimmunol 2009, 216(1-2):92-97.
59. Bermejo P., Martin-Aragon S., Benedi J., et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008, 117(2):198-202.
60. Seppala T.T., Herukka S.K., Hanninen T., et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. JNeurol Neurosurg Psychiatry 2010, 81(10):1123-1127.
61. Le Bastard N., Leurs J., Blomme W., et al. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. JAlzheimers Dis 2010, 21(1):291-301.
62. Lui J.K., Laws S.M., Li Q.X., et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. JAlzheimers Dis 2010, 20(4):1233-1242.
63. Lewczuk P., Kornhuber J., Vanmechelen E., et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol 2010, 223(2):366-370.
64. Blennow K., Zetterberg H. Use of CSF biomarkers in Alzheimer's disease clinical trials. JNutr Health Aging 2009, 13(4):358-361.
65. Kester M.I., Verwey N.A., van Elk E.J., et al. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010, 31(4):539-540. [author reply: 541].
66. Schupf N., Tang M.X., Fukuyama H., et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 2008, 105(37):14052-14057.
67. Thambisetty M., Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010, 4(1):65-79.
68. Guntert A., Campbell J., Saleem M., et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. JAlzheimers Dis 2010, 21(2):585-596.
69. Gupta V.B., Laws S.M., Villemagne V.L., et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 2011, 76(12):1091-1098.
70. Llano D.A., Devanarayan V., Simon A.J., et al. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 2013, 27(3):233-243. The Alzheimer's Disease Neuroimaging Initiative.
71. 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. JAlzheimers Dis 2013, 33(4):929-939.
72. Tschanz J.T., Welsh-Bohmer K.A., Lyketsos C.G., et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology 2006, 67(2):229-234.
73. Elias-Sonnenschein L.S., Viechtbauer W., Ramakers I.H., et al. Predictive value of APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis. JNeurol Neurosurg Psychiatry 2011, 82(10):1149-1156.
74. Tyas S.L., Salazar J.C., Snowdon D.A., et al. Transitions to mild cognitive impairments, dementia, and death: Findings from the nun study. Am J Epidemiol 2007, 165(11):1231-1238.
75. Rodriguez-Rodriguez E., Sanchez-Juan P., Vazquez-Higuera J.L., et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. JNeural Transm 2013, 120(5):807-812.
76. Guo L.H., Alexopoulos P., Eisele T., et al. The National Institute on Aging-Alzheimer'sAssociation research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome. Eur Arch Psychiatry Clin Neurosci 2013, 263(4):325-333.
77. Jack C.R., Knopman D.S., Weigand S.D., et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71(6):765-775.
78. Ravaglia G., Forti P., Montesi F., et al. Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. JAm Geriatr Soc 2008, 56(1):51-58.
79. Zhou B., Nakatani E., Teramukai S., et al. Risk classification in mild cognitive impairment patients for developing Alzheimer's disease. JAlzheimers Dis 2012, 30(2):367-375. Alzheimer's Disease Neuroimaging I.
80. Koepsell T.D., Monsell S.E. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology 2012, 79(15):1591-1598.
81. Campbell N.L., Boustani M.A., Lane K.A., et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010, 75(2):152-159.
82. Schubert C.C., Boustani M., Callahan C.M., et al. Comorbidity profile of dementia patients in primary care: are they sicker?. JAm Geriatr Soc 2006, 54(1):104-109.
83. Murray M.D., Young J., Hoke S., et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med 2007, 146(10):714-725.
84. Nahin R.L., Pecha M., Welmerink D.B., et al. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. JAm Geriatr Soc 2009, 57(7):1197-1205.
85. Murray M.D., Lane K.A., Gao S., et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002, 162(18):2090-2096.
86. Gorelick P.B., Scuteri A., Black S.E., et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42(9):2672-2713.
87. Launer L.J., Ross G.W., Petrovitch H., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000, 21(1):49-55.
88. Kivipelto M., Helkala E.L., Laakso M.P., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001, 322(7300):1447-1451.
89. Hanon O., Berrou J.P., Negre-Pages L., et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function and Systolic Blood Pressure Reduction open-label study. JHypertens 2008, 26(8):1642-1650.
90. Lyketsos C.G., Toone L., Tschanz J., et al. Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry 2005, 13(8):656-664.
91. Solfrizzi V., Scafato E., Capurso C., et al. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. Neurobiol Aging 2011, 32(11):1932-1941.
92. Li L., Wang Y., Yan J., et al. Clinical predictors of cognitive decline in patients with mild cognitive impairment: the Chongqing aging study. JNeurol 2012, 259(7):1303-1311.
93. Clerici F., Caracciolo B., Cova I., et al. Does vascular burden contribute to the progression of mild cognitive impairment to dementia?. Dement Geriatr Cogn Disord 2012, 34(3-4):235-243.
94. Ravaglia G., Forti P., Maioli F., et al. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dement Geriatr Cogn Disord 2006, 21(1):51-58.
95. DeCarli C., Mungas D., Harvey D., et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004, 63(2):220-227.
96. Wolf H., Ecke G.M., Bettin S., et al. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriatr Psychiatry 2000, 15(9):803-812.
97. Xu W.L., Qiu C.X., Wahlin A., et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63(7):1181-1186.
98. Xu W., Caracciolo B., Wang H.X., et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010, 59(11):2928-2935.
99. Li J., Wang Y.J., Zhang M., et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011, 76(17):1485-1491.
100. Hoffman L.B., Schmeidler J., Lesser G.T., et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009, 72:1720-1726.
101. Bettermann K., Arnold A.M., Williamson J., et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. JStroke Cerebrovasc Dis 2012, 21(6):436-444.
102. Peters M.E., Rosenberg P.B., Steinberg M., et al. Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study. Am J Geriatr Psychiatry 2012, 20(5):416-424.
103. Lyketsos C.G., Colenda C.C., Beck C., et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006, 14(7):561-572.
104. Peters M.E., Rosenberg P.B., Steinberg M., et al. Neuropsychiatric symptoms as risk factors for progression from CIND to Dementia: The Cache County Study. Am J Geriatr Psychiatry 2013, [Epub ahead of print]. http://dx.doi.org/10.1016/j.jagp.2013.01.049.
105. Richard E., Schmand B., Eikelenboom P., et al. Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. Dement Geriatr Cogn Disord 2012, 33(2-3):204-209.
106. Modrego P.J., Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004, 61(8):1290-1293.
107. Palmer K., Berger A.K., Monastero R., et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007, 68(19):1596-1602.
108. Reynolds C.F., Butters M.A., Lopez O., et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011, 68(1):51-60.
109. Richard E., Reitz C., Honig L.H., et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol 2013, 70(3):374-382.